drugset
Drugs / Recombinant Human Papillomavirus Nonavalent Vaccine
last change Aug 2026 re-read 3 minutes ago

Recombinant Human Papillomavirus Nonavalent Vaccine

also known as Gardasil 9

Vaccine

Developed for
cervical carcinoma · human papilloma virus infection · anogenital human papillomavirus infection · carcinoma · cervical intraepithelial neoplasia grade 2/3 · human papillomavirus-related squamous cell carcinoma · squamous cell intraepithelial neoplasia
Investigated by
National Cancer Institute (NCI) · Fred Hutchinson Cancer Center · AIDS Malignancy Consortium · AIDS and Cancer Specimen Resource · Asociación Civil Via Libre, Peru · Bill and Melinda Gates Foundation
+6 more · Evandro Chagas National Institute of Infectious Diseases (INI), Oswaldo Cruz Foundation (FIOCRUZ) · GHESKIO Center · Merck Sharp & Dohme LLC · The Emmes Company, LLC · University of Arkansas · University of California, Los Angeles

Trials 7

today NCT05985681 · Ph 1 NCT04265950 · Ph 4 NCT05237947 · Ph 4 NCT03284866 · Ph 3 NCT03180034 · Ph 4 NCT03051516 · Ph 4 NCT03036930 · Ph 2
20182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05985681 Jan 2026 → Feb 2028 expected carcinoma National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT03036930 Jun 2017 → Mar 2024 overdue human papilloma virus infection, human papillomavirus-related squamous cell carcinoma National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT03284866 Jul 2019 → Nov 2024 HIV infectious disease, anogenital human papillomavirus infection, cervical intraepithelial neoplasia grade 2/3 AIDS Malignancy Consortium Completed No outcome recorded
Phase 44 trials · 1 met primary · 1 missed
Phase 4 NCT04265950 Mar 2022 → May 2026 HIV infectious disease Fred Hutchinson Cancer Center Completed No outcome recorded
Phase 4 NCT05237947 Mar 2022 → Aug 2026 overdue cervical carcinoma National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 4 NCT03180034 Nov 2017 → Aug 2025 overdue cervical carcinoma, human papilloma virus infection National Cancer Institute (NCI) Active not recruiting Met primary
Phase 4 NCT03051516 Aug 2017 → Dec 2022 squamous cell intraepithelial neoplasia Fred Hutchinson Cancer Center Terminated Missed primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as Recombinant Human Papillomavirus Nonavalent Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT03051516 ↗
6

NCT05985681 ↗

NCT03036930 ↗

NCT04265950 ↗

NCT05237947 ↗

NCT03180034 ↗

NCT03284866 ↗
Known as Gardasil 9 “OBJECTIVE: To test whether the licensed prophylactic HPV vaccine (Gardasil-9) can reduce the risk of HSIL recurrence by 50% in previously unvaccinated individuals recently...” PMID 30977845 ↗ Apr 2019
2

“9-valent HPV (9vHPV) vaccine, Gardasil-9” PMID 39871186 ↗ Jan 2025

“Gardasil 9” NCT05985681 ↗
Modality Vaccine “recombinant human papillomavirus nonavalent vaccine” NCT03036930 ↗
Route Intramuscular “Given IM” NCT03036930 ↗